phrykt

Century Therapeutics, Inc. (IPSC): who owns it and who trades it

As of Nov 16, 2026, IPSC insiders reported 20 open-market sales worth $86.3K and 3 purchases worth $97K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gregory Russotti (See Remarks), with $40.1K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Century Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IPSC

99 funds and institutions reported IPSC shares worth $388M at the end of Q2 2026, about 88% of the company. The largest holder is Ra Capital Management, L.P. with 9.8%.

Funds and institutions (13F) 88%Everyone else 12%

10 largest owners, by share of the company

Ra Capital Management, L.P.9.8%
TCG Crossover Management, LLC9.8%
Versant Venture Management, LLC6.7%
Deep Track Capital, LP5.2%
Venrock Adviser, LLC4.8%
Commodore Capital LP4.8%
Rtw Investments, LP4.8%
BlackRock, Inc.4.5%
Vanguard Capital Management LLC3.2%
Balyasny Asset Management L.P.3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.17.75M9.84%$43.5MNo change
TCG Crossover Management, LLC17.75M9.84%$43.4MNo change
Versant Venture Management, LLC12.17M6.75%$29.8MNo change
Deep Track Capital, LP9.46M5.25%$23.2M-0%
Venrock Adviser, LLC8.70M4.82%$21.3MNo change
Commodore Capital LP8.70M4.82%$21.3MNo change
Rtw Investments, LP8.70M4.82%$21.3MNo change
BlackRock, Inc.8.09M4.49%$19.8M+431%
Vanguard Capital Management LLC5.70M3.16%$14M+0%
Balyasny Asset Management L.P.5.52M3.06%$13.5M+10%
Point72 Asset Management, L.P.4.98M2.76%$12.2M-16%
Seven Fleet Capital Management LP4.35M2.41%$10.7M+47%
Woodline Partners LP4.26M2.36%$10.4M+40%
Millennium Management LLC4.19M2.33%$10.3M-10%
Trails Edge Capital Partners, LP4.13M2.29%$10.1M+69%
Spruce Street Capital LP4.06M2.25%$9.9MNo change
Adage Capital Partners Gp, L.l.c.3.79M2.10%$9.3MNo change
Geode Capital Management, LLC2.98M1.65%$7.3M+129%
Two Sigma Investments, LP2.70M1.50%$6.6M+14%
DAFNA Capital Management LLC2.40M1.33%$5.9M-1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IPSC insiders reported $97K of open-market purchases and $86.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$97K
3 trades, 2 people
Sales, 12 months
$86.3K
20 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 5, 2026

Purchases and sales by month

$79.5K$79.5KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026Douglas CarrVice presidentSale266$1.52$404Form 4
Sep 14, 2026Gregory RussottiSee RemarksSale2,587$1.93$5KForm 4
Sep 14, 2026Douglas CarrVice presidentSale1,658$1.93$3.2KForm 4
Sep 8, 2026Gregory RussottiSee RemarksSale534$2.05$1.1KForm 4
Sep 8, 2026Douglas CarrVice presidentSale254$2.05$521Form 4
Aug 3, 2026Douglas CarrVice presidentSale275$1.98$544Form 4
Jun 12, 2026Gregory RussottiSee RemarksSale2,584$2.23$5.8KForm 4
Jun 12, 2026Douglas CarrVice presidentSale1,654$2.23$3.7KForm 4
Jun 8, 2026Gregory RussottiSee RemarksSale524$2.11$1.1KForm 4
Jun 8, 2026Douglas CarrVice presidentSale249$2.11$525Form 4
May 4, 2026Douglas CarrVice presidentSale264$2.34$618Form 4
Mar 12, 2026Douglas CarrVice presidentSale7,043$2.55$18KForm 4
Mar 12, 2026Gregory RussottiSee RemarksSale10,076$2.55$25.7KForm 4
Mar 9, 2026Gregory RussottiSee RemarksSale479$2.54$1.2KForm 4
Mar 9, 2026Douglas CarrVice presidentSale247$2.54$627Form 4
Feb 3, 2026Douglas CarrVice presidentSale323$1.82$588Form 4
Dec 22, 2025Chad CowanChief Scientific OfficerPurchase58,060$0.85$49.4KForm 4
Dec 12, 2025Brent PfeiffenbergerCEOPurchase52,000$0.58$30.2KForm 4
Dec 8, 2025Douglas CarrVice presidentSale257$0.53$136Form 4
Dec 8, 2025Gregory RussottiSee RemarksSale526$0.53$279Form 4
Nov 20, 2025Chad CowanChief Scientific OfficerSale5,462$0.50$2.7KForm 4
Nov 19, 2025Brent PfeiffenbergerCEOPurchase35,000$0.50$17.5KForm 4
Nov 17, 2025Brent PfeiffenbergerCEOSale32,456$0.45$14.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brent PfeiffenbergerPresident and CEO, Director$47.7K$14.6KDec 12, 2025
Chad CowanChief Scientific Officer$49.4K$2.7KDec 22, 2025
Gregory RussottiSee Remarks–$40.1KSep 14, 2026
Douglas CarrSVP Finance & Operations–$28.8KNov 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IPSC short interest

High short interest. 17.7% of IPSC shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 162%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 32.03M IPSC shares were sold short, 17.7% of the shares outstanding, up 9.9% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 31.0 trading days (days to cover).

Shares short, % of all shares

17.7%May 15Oct 3019.3%

Days to cover

31.0May 15Oct 3089.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202632.03M17.69%+10%1.03M31.0
Oct 15, 202629.13M16.09%-0%996,28729.2
Sep 30, 202629.22M16.14%-0%573,91150.9
Sep 15, 202629.35M16.21%-1%373,30078.6
Aug 31, 202629.53M16.31%+1%418,03170.6
Aug 14, 202629.37M16.22%-1%573,91851.2
Jul 31, 202629.82M16.53%+5%732,46640.7
Jul 15, 202628.38M15.74%+21%1.29M22.0
Jun 30, 202623.46M13.01%+52%3.00M7.8
Jun 15, 202615.41M8.54%+24%975,90415.8
May 29, 202612.47M6.91%+2%921,55513.5
May 15, 202612.21M6.77%+1%653,37118.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Century Therapeutics company events

Century Therapeutics filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 2, 2026.

  1. Oct 2, 2026AnnouncementA copy of the slides presented by the Company at EASD is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
  2. Sep 9, 2026LeadershipThe Board of Directors of Century Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to seven directors and appointed Mr. Joseph Truitt as a member of the Board, effective as of September 9, 2026. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jun 16, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
  5. Jun 12, 2026VoteReported shareholder vote results. Filing
  6. Jun 8, 2026AnnouncementCentury Therapeutics, Inc. issued a press release announcing that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the American Diabetes Association (ADA) 2026 Scientific Sessions being held June 5-8 th in New Orleans, Louisiana. Filing
  7. May 13, 2026ResultsReleased financial results. Filing
  8. Mar 26, 2026AnnouncementCentury Therapeutics, Inc. filed with the Securities and Exchange Commission a shelf registration statement on Form S-3 (File No. 333-288616), which became effective on January 9, 2026, and replaced the Company’s previous shelf registration statement on Form S-3 (File No. 333-265975) filed with the… Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Jan 23, 2026AnnouncementAlso on January 22, 2026, the Company received of a letter from the Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share and that it is now in… Filing
  11. Jan 12, 2026AnnouncementShared information with investors. Filing
  12. Jan 8, 2026AgreementCentury Therapeutics, Inc., entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares of common stock, par value $0.0001 per share, of the… Filing
  13. Dec 29, 2025LeadershipCarlo Rizzuto, Ph.D. notified the board of directors of Century Therapeutics, Inc. of his intent to resign from the Board, effective December 18, 2025. Filing
  14. Dec 12, 2025AnnouncementShared information with investors. Filing
  15. Dec 9, 2025LeadershipThe Board of Directors of Century Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to eight directors and appointed Dr. Martin Murphy and Dr. Han Lee as directors of the Board, effective as of December 9, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Century Therapeutics financials

Famous investors that hold IPSC

4 of the 50 well-known investors we track reported holding IPSC in their latest 13F filing. The largest position is Israel Englander's, worth $10.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20266.05M$10.4M0.0%+44%
Steve Cohen · Point72 Asset ManagementQ3 20265.11M$8.7M0.0%+3%
Jim Simons · Renaissance TechnologiesQ3 20261.07M$1.8M0.0%-15%
Ken Griffin · Citadel AdvisorsQ3 202684,660$145K0.0%-33%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Century Therapeutics, Inc. (IPSC) stock

Who owns the most IPSC stock?

The largest reported owner of Century Therapeutics, Inc. (IPSC) is Ra Capital Management, L.P., with 9.8% of the company. In total, 99 funds and institutions reported holding IPSC at the end of Q2 2026, together about 88% of the shares. See the largest owners.

Are IPSC insiders buying or selling?

In the last 12 months, IPSC insiders reported 3 open-market purchases worth $97K and 20 sales worth $86.3K. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in IPSC?

As of Oct 30, 2026, 32.03M IPSC shares were sold short, 17.7% of the shares outstanding, up 9.9% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 31.0 trading days (days to cover). See the history.

Which famous investors hold IPSC?

4 of the 50 well-known investors we track reported IPSC in their latest 13F filing, including Israel Englander, Steve Cohen, Jim Simons. The largest position is worth $10.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.